Cargando…
Heterogeneity in cardiovascular death or hospitalization for heart failure benefits with flozins is linked to weight
AIMS: Cardiovascular outcome trials with sodium–glucose cotransporter 2 inhibitors (SGLT‐2is) have documented a positive impact on micro‐ and macrovascular complications of type 2 diabetes (T2D). Most analyses suggest that these benefits are independent of achieving metabolic control. This meta‐regr...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10053285/ https://www.ncbi.nlm.nih.gov/pubmed/36707061 http://dx.doi.org/10.1002/ehf2.14296 |
_version_ | 1785015377470685184 |
---|---|
author | Ghosal, Samit Sinha, Binayak Mukherjee, Rik |
author_facet | Ghosal, Samit Sinha, Binayak Mukherjee, Rik |
author_sort | Ghosal, Samit |
collection | PubMed |
description | AIMS: Cardiovascular outcome trials with sodium–glucose cotransporter 2 inhibitors (SGLT‐2is) have documented a positive impact on micro‐ and macrovascular complications of type 2 diabetes (T2D). Most analyses suggest that these benefits are independent of achieving metabolic control. This meta‐regression analysis was undertaken to explore the relationship between metabolic components positively influenced by SGLT‐2is and a reduction in cardiovascular death (CV death) or hospitalization due to heart failure (hHF). METHODS AND RESULTS: A database search was conducted using the Cochrane Library to identify relevant studies. Analysis was conducted using CMA and RStudio (2022.07.1) software. The hazard ratios of the individual studies were used to compute the random effects model mean effect size for CV death or hHF, and the prediction interval was used to identify the uncertainty in the summary treatment effect. Heterogeneity was quantified using Q statistics. A pooled population of 46 969 patients from five studies was included for analysis. The Cochrane risk of bias tool was used to assess the quality of the studies. There was a significant 23% reduction in CV deaths or hHFs in the SGLT‐2i arm compared with the placebo arm [hazard ratio (HR): 0.77, 95% confidence interval (CI) 0.70–0.85]. However, the prediction interval (0.57–1.05) and the Q statistics [8.06 > degrees of freedom (df) of 4] were indicative of uncertainty in the true effect or heterogeneity. Nearly 50% of the variance of the observed effects were related to the true effects (I (2) = 50%). Among the moderators selected, a significant correlation of the outcomes was found with the weight variable (P < 0.01). Weight differential could explain the entire variance in true effect size (R (2) = 1.00) ruling out any sampling error. CONCLUSIONS: The results of this meta‐regression analysis suggest that the beneficial effects of SGLT‐2is in reducing CV deaths and hHFs are related to the weight variable. |
format | Online Article Text |
id | pubmed-10053285 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-100532852023-03-30 Heterogeneity in cardiovascular death or hospitalization for heart failure benefits with flozins is linked to weight Ghosal, Samit Sinha, Binayak Mukherjee, Rik ESC Heart Fail Original Articles AIMS: Cardiovascular outcome trials with sodium–glucose cotransporter 2 inhibitors (SGLT‐2is) have documented a positive impact on micro‐ and macrovascular complications of type 2 diabetes (T2D). Most analyses suggest that these benefits are independent of achieving metabolic control. This meta‐regression analysis was undertaken to explore the relationship between metabolic components positively influenced by SGLT‐2is and a reduction in cardiovascular death (CV death) or hospitalization due to heart failure (hHF). METHODS AND RESULTS: A database search was conducted using the Cochrane Library to identify relevant studies. Analysis was conducted using CMA and RStudio (2022.07.1) software. The hazard ratios of the individual studies were used to compute the random effects model mean effect size for CV death or hHF, and the prediction interval was used to identify the uncertainty in the summary treatment effect. Heterogeneity was quantified using Q statistics. A pooled population of 46 969 patients from five studies was included for analysis. The Cochrane risk of bias tool was used to assess the quality of the studies. There was a significant 23% reduction in CV deaths or hHFs in the SGLT‐2i arm compared with the placebo arm [hazard ratio (HR): 0.77, 95% confidence interval (CI) 0.70–0.85]. However, the prediction interval (0.57–1.05) and the Q statistics [8.06 > degrees of freedom (df) of 4] were indicative of uncertainty in the true effect or heterogeneity. Nearly 50% of the variance of the observed effects were related to the true effects (I (2) = 50%). Among the moderators selected, a significant correlation of the outcomes was found with the weight variable (P < 0.01). Weight differential could explain the entire variance in true effect size (R (2) = 1.00) ruling out any sampling error. CONCLUSIONS: The results of this meta‐regression analysis suggest that the beneficial effects of SGLT‐2is in reducing CV deaths and hHFs are related to the weight variable. John Wiley and Sons Inc. 2023-01-27 /pmc/articles/PMC10053285/ /pubmed/36707061 http://dx.doi.org/10.1002/ehf2.14296 Text en © 2023 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Articles Ghosal, Samit Sinha, Binayak Mukherjee, Rik Heterogeneity in cardiovascular death or hospitalization for heart failure benefits with flozins is linked to weight |
title | Heterogeneity in cardiovascular death or hospitalization for heart failure benefits with flozins is linked to weight |
title_full | Heterogeneity in cardiovascular death or hospitalization for heart failure benefits with flozins is linked to weight |
title_fullStr | Heterogeneity in cardiovascular death or hospitalization for heart failure benefits with flozins is linked to weight |
title_full_unstemmed | Heterogeneity in cardiovascular death or hospitalization for heart failure benefits with flozins is linked to weight |
title_short | Heterogeneity in cardiovascular death or hospitalization for heart failure benefits with flozins is linked to weight |
title_sort | heterogeneity in cardiovascular death or hospitalization for heart failure benefits with flozins is linked to weight |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10053285/ https://www.ncbi.nlm.nih.gov/pubmed/36707061 http://dx.doi.org/10.1002/ehf2.14296 |
work_keys_str_mv | AT ghosalsamit heterogeneityincardiovasculardeathorhospitalizationforheartfailurebenefitswithflozinsislinkedtoweight AT sinhabinayak heterogeneityincardiovasculardeathorhospitalizationforheartfailurebenefitswithflozinsislinkedtoweight AT mukherjeerik heterogeneityincardiovasculardeathorhospitalizationforheartfailurebenefitswithflozinsislinkedtoweight |